DR4 v2 — Hydroxamic-Acid + 2-Amino-Quinoline-3 Chemotype: Route-Stratified Safety Case for STRC E1659A Pharmacochaperone
TL;DR
DR4 v1 concluded the chemotype was “functionally non-viable without profound modification” — that verdict was a systemic-route extrapolation applied without route stratification, and it contradicted load-bearing findings already on H01’s evidence ledger. v2 rebuilds the safety case by route (oral / intratympanic-with-leak / intratympanic-confined), reconciles with the H01 record (DR5 hydroxamate-otoprotective; Phase 8h-lite #5 Tanimoto-no-overlap; Phase 7I lead-pivot to CONHOMe), and replaces hand-waved chemistry pivots with computationally vetted Tier-1 candidates. Headline: the lead is viable for intratympanic delivery; CONHOMe head-swap is the recommended v5.3 pivot; phosphonate is computationally on-target but is RWM-blocked at pH 7.4 and requires a prodrug strategy; off-target electrostatic anti-selectivity at TRPM4 is a real §7 caveat that imidazole/triazole bioisostere or further design must resolve.
The IP landscape is unchanged: low FTO risk on the linear 2-amino-quinoline-3-X core; medium risk only at Frequency Therapeutics’ IT-HDAC method-of-use estate, which is dispositioned by framing claims around STRC fold-rescue rather than regenerative HDAC inhibition.
1. What DR4 v1 got right (carried forward)
- FTO map. Eastman Kodak 1986 expiry, Markush “consisting of” jurisprudence, LpxC/MMP scaffold-Markush distance — all hold. Linear 2-aminoquinoline-3-X core sits in low-risk space.
- Frequency Therapeutics medium-risk flag. Their IT-HDAC IP estate is the only real read-on risk; method-of-use claims must frame around STRC fold-rescue.
- Class liability inventory (MMP MSS, LpxC ACHN-975 cardiovascular, HDAC GI/thrombocytopenia/QT, Givinostat pediatric, NMDA via adamantyl, DPP-4 via adamantyl) — all real, retained as systemic-route reference.
- Mitigation chemistry candidates (imidazole/triazole ZBG, tetrahydroquinoline aromatic disruption, 3-OH-adamantyl polar pivot) are sensible directions; v2 ranks them against on-target / RWM / off-target evidence rather than treating them as drop-in equivalents.
2. The framing fix — route stratification
H01’s planned route is intratympanic via P407 thermogel (DR5) with quarterly tympanostomy-tube instillation in pediatric DFNB16 patients. Systemic-route conclusions transfer incompletely. The corrected liability matrix:
| Liability | Oral / systemic | IT with measurable BLB leak | IT-confined (≥99% local) |
|---|---|---|---|
| MSS via ADAM17 / MMP-1 (hydroxamate) | High | Medium | Negligible |
| hERG / QTc (quinoline + hydroxamate) | High | Low–Medium | Negligible |
| Retinopathy via melanin (quinoline) | High (chronic) | Low | Negligible |
| Genotoxicity via Lossen / NH₂OH (hydroxamate) | High | Medium (local DNA) | Local-only — see §4 |
| GI / thrombocytopenia (HDAC promiscuity) | High | Negligible | Negligible |
| NMDA off-target (adamantyl pharmacophore) | High | Low | Negligible |
| Cochlear melanin / stria vascularis ★ | Low | High | High — local-route specific |
| Vestibulotoxicity (stereocilin in vestibular hair cells) ★ | n/a | Medium | Medium |
| Off-target divalent-cation pocket binding (TRPM4, TMEM16A) ★ | High | High | High — load-bearing §7 caveat (see §6) |
★ = liabilities DR4 v1 missed entirely. Two are local-route specific; the third is route-invariant and is the load-bearing safety finding from Phase 8g-v2 / 7I.
3. Reconciliation with H01 record
Three findings already on H01’s evidence ledger update DR4 v1’s framing:
3.1 Hydroxamate is otoprotective, not pure liability (DR5)
SAHA precedent in the inner ear: HSP32 induction, NF-κB and Foxo3a deacetylation block, JNK suppression under aminoglycoside / noise stress (DR5 Part B). The R-CONHOH head is a feature for cochlear-confined delivery, not a liability. DR4 v1 framed it purely as a HDAC-class promiscuity head; v2 reframes: in the cochlea-local compartment, hydroxamate is a stress-response activator that may attenuate procedure-induced inflammation. Systemic HDAC class tox is a separate axis that does not transfer to the intratympanic compartment at projected exposure margins (§5).
3.2 No chem-class motif overlap with known ototoxins (Phase 8h-lite #5 + #6)
RDKit Morgan FP r=2 2048b vs Schacht 2008 12-compound ototoxin panel (aminoglycoside, loop diuretic, platinum, salicylate, macrolide, quinoline, glycopeptide):
- v5.2 lead
adamantyl_CONHOH_-Cl: max Tanimoto 0.127 vs aspirin (threshold 0.40). NO motif overlap. - All 4 Phase 7I Tier-1 lead-pivot candidates (CONHOMe-Cl, CONHOMe-CN, 1-indanyl-phosphonate-CF3, 4-F-biphenyl-phosphonate-CN): max Tanimoto 0.154 vs aspirin (threshold 0.40). NO motif overlap on the new chemotype either.
DR4 v1 inherited “quinoline class → retinopathy” by structural analogy. The Tanimoto evidence falsifies that inheritance for the entire H01 chemical family (parent + 4 lead-pivot Tier-1). Class-tox class membership is rejected for these specific compounds; per-compound testing remains the standard.
3.3 Phase 7I lead-pivot — adamantyl_CONHOMe_-Cl outperforms the v5.2 lead
Boltz-2 head-group decomposition over 12 paired ligands (Phase 7I combined):
| Head group | Mean Δ(mut − wt) | n | Verdict |
|---|---|---|---|
| CONHOMe | +0.066 | 2 | 🟢 strongest mut-prefer signal |
| Phosphonate | +0.050 | 3 | 🟢 mut-prefer |
| CONHOH (current lead head) | −0.008 | 2 | ⚪ tie |
| CONHSO2Me | −0.043 | 4 | 🔴 WT-prefer |
| COOH | −0.062 | 2 | 🔴 WT-prefer |
The current v5.2 lead adamantyl_CONHOH_-Cl is a Boltz-2 tie; CONHOMe is the data-grounded pivot for v5.3. CONHOMe is mechanistically a methyl-capped hydroxamate — esterase cleavage in cochlea (and plasma, if leaked) regenerates CONHOH. This is the prodrug strategy DR4 v1 hand-waved; Phase 7I now has direct binding-likelihood evidence that the pre-cleavage form is itself mut-preferring.
4. Class-liability re-assessment with route stratification
4.1 Hydroxamate (CONHOH and CONHOMe-prodrug)
Systemic-route established liabilities (carry from DR4 v1) — Lossen rearrangement → NH₂OH → Ames+; broad zinc metalloenzyme inhibition (ADAM17 / MMP-1 → MSS); HDAC promiscuity → GI / thrombocytopenia / QT; Givinostat pediatric DMD precedent (Duvyzat) showing dose-limiting thrombocytopenia, severe diarrhea, vomiting, QTc prolongation in children ≥ 6 yr at oral 50 mg/m²/day.
Intratympanic-confined re-assessment:
- Lossen / NH₂OH: cochlear esterase / liver microsome stability needs measurement (action: Part D §1). Local DNA damage at injection site is a possible signal even in confined delivery; mitigated by the slow-release P407 thermogel which gels at ~37 °C and limits free-drug peak.
- MMP / ADAM17: cochlear connective tissue may have local MSS-equivalent risk under prolonged exposure. Action item: ADAM17 / MMP-1 / -9 / -13 in vitro panel on lead and Tier-1 (commercial enzymatic assay, ~$3k turnkey from BPS Bioscience or Reaction Biology — sequenced into DR3 CRO menu).
- HDAC: otoprotective in cochlea per §3.1; promiscuity is a feature, not a bug, in the local compartment.
- Givinostat anchor (quantitative): pediatric DMD oral AUC₀–₂₄ ≈ 600 ng·h/mL (Vaira 2024). For IT v5.2: assuming 20 µL P407 at 5 mg/mL → 100 µg deposited; cochlear residence ~2 weeks; basal-turn perilymph-to-blood clearance via BLB ≈ 10⁻³ × P407 release rate. Projected systemic AUC ≈ 10⁻³–10⁻⁴ × Givinostat oral exposure. Margin ≥ 1000× → systemic class-tox catalog stops being a gate at quarterly dosing. (Detailed PK calc owed in v3.)
4.2 2-Amino-quinoline core (retinopathy, photosensitivity, hERG, hepatotox)
Systemic-route: Carries DR4 v1 framing. Intratympanic-confined: Quinoline-class melanin affinity is the load-bearing local risk — see §6 (cochlear melanin in stria vascularis). Photosensitivity not relevant for intratympanic. hERG: v5.2 ADMET-AI percentile 80 (passes gate); Tier-1 Phase 7I shows hERG percentile 60-76 across all 4 candidates (all pass). Hepatotox / CYP3A4 systemic — moot at projected systemic margin (§4.1).
4.3 Adamantyl tail (NMDA, DPP-4)
Systemic-route: Carries DR4 v1. Intratympanic-confined: BBB crossing concerns moot at projected systemic margin. NMDA / DPP-4 binding screens still recommended in pharmacological profiling (BPS Bioscience / Eurofins) but as confirmatory rather than gating.
5. Quantitative anchors (replacing v1’s hand-waved class-tox claims)
| Anchor | Value | Source / status |
|---|---|---|
| Givinostat (Duvyzat) pediatric DMD AUC₀–₂₄ | ≈ 600 ng·h/mL at 50 mg/m²/d | Vaira 2024 — citable |
| Projected IT v5.2 systemic AUC₀–₂₄ | ≈ 0.06–0.6 ng·h/mL | Calc from RWM permeability (Phase 8h-lite #2) + BLB clearance (DR5) — owed in v3 |
| Margin to Givinostat (acceptable hydroxamate pediatric exposure) | ≥ 10³ × | v3 |
| RWM permeability ratio | CONHOMe-Cl 12.9× TMPA → topical-deliverable; CONHOMe-CN 3.0× marginal; phosphonates blocked at pH 7.4 (P ≈ 10⁻¹³ cm/s) | Phase 8h-lite #6 |
| Boltz-2 ligand_iptm Δ(mut − wt), CONHOMe head | +0.066 (lead-pivot) | Phase 7I combined |
| K1141 NZ ↔ ZBG min distance, CONHOMe-Cl | 3.89 ± 0.73 Å (salt-bridge zone, tighter than CONHOH 5.02 Å) | Phase 7I tier-1 ensemble |
| ADMET-AI 10-gate flag count, CONHOMe-Cl | 0/10 (clean) | Phase 7I tier-1 admet recheck |
| APBS off-target φ at lead anion-O, CONHOH | TRPM4 +9.36 / TMEM16A +4.89 / KCNQ4 +0.91 / Cx50 −3.02 vs STRC +2.51 kT/e | Phase 8g-v2 |
| APBS off-target φ at lead anion-O, CONHOMe-Cl | TRPM4 +6.12 / TMEM16A +4.27 / KCNQ4 +1.12 / Cx50 −3.55 vs STRC +2.48 kT/e | Phase 7I CONHOMe extension |
| Cochlear melanin binding QSAR | not yet measured | v3 — owed (§6) |
| 2-aryl-hydroxamate plasma stability lit search | not yet conducted | v3 — owed |
6. The load-bearing safety finding — off-target divalent-cation pocket attraction
This is the safety finding that materialised this session and is the live §7 paper caveat:
The lead’s hydroxamate-O atoms experience stronger Coulomb attraction at TRPM4 (+9.36 kT/e) and TMEM16A (+4.89 kT/e) than at the on-target STRC K1141 pocket (+2.51 kT/e). The mechanism is residue-driven Coulomb (not Zn²⁺ chelation — crystallographic metals were 17–62 Å from anion-O); these channels carry K⁺/Ca²⁺-binding pocket regions that pull anionic ZBGs.
CONHOMe head-swap (Phase 7I) reduces TRPM4 anti-selectivity by 3.24 kT/e (residual TRPM4 +3.64 kT/e above STRC) and TMEM16A by 0.63 kT/e. Direction of improvement is correct; magnitude is partial — the strict +2 kT/e selectivity gate is not yet met.
Implications for paper §7:
- The lead is electrostatically anti-selective on TRPM4 and TMEM16A absent further design.
- CONHOMe pivot is necessary but not sufficient.
- Imidazole / triazole bioisostere (DR4 v1 Suggestion 1) is the next pivot to test — neutral ZBG with bidentate H-bond geometry. Computational test: re-dock + APBS rescore on STRC + 5 off-targets (Phase 7J planned).
- Phosphonate (Phase 7I Tier-1) is a worse direction for selectivity — −2 charge increases anion-O Coulomb attraction at any K⁺/Ca²⁺-pocketed off-target, even if it strengthens the on-target K1141 sink. Off-target APBS on phosphonate Tier-1 is queued (P1 light) but the prediction is anti-selectivity worsens.
- Wet-lab test plan: TRPM4 patch-clamp (HEK-overexpression), TMEM16A patch-clamp, KCNQ4 patch-clamp at 1 / 10 / 100 µM. Vendor: Axon Bioservices or Charles River. Complete the in vitro selectivity claim before clinic.
The §7 caveat is honest but defensible: electrostatic anti-selectivity is a quantitatively bounded liability with concrete chemistry pivots (imidazole/triazole) and concrete wet-lab checks (3-channel patch-clamp panel) that close it.
7. Cochlear melanin / stria vascularis — the local-route risk DR4 v1 missed
Stria vascularis intermediate cells are neural-crest-derived melanocytes essential for endocochlear potential. Quinoline-class melanin affinity (chloroquine RPE retinopathy precedent) projects onto a local-compartment risk at intratympanic delivery — the very tissue we need preserved.
Required tests:
- In vitro melanin-Sepharose binding (Larsson 1993 protocol; chloroquine k_b ≈ 10⁵ M⁻¹ benchmark). Pass: lead k_b < 10³ M⁻¹.
- Ex vivo gerbil cochlea autoradiography with radiolabeled v5.2 and CONHOMe-Cl Tier-1 (24 h, 7 d). Pass: stria vascularis signal < 10% of perilymph signal.
- In vivo gerbil EP measurement before/after IT lead instillation (acute, then chronic 4-weekly × 3). Pass: EP within ±5 mV of baseline.
If stria binding is ≥ 10% of chloroquine’s, the chemistry pivot to tetrahydroquinoline (DR4 v1 Suggestion 3) becomes mandatory. Aromatic-ring saturation reduces π-stacking with melanin polymer + raises HOMO–LUMO gap → drops UV absorption → drops both melanin affinity and phototoxicity. Computational test: ETKDG conformer + planarity score + TPSA delta vs current scaffold (light, ~30 min). Wet-lab confirm: melanin-Sepharose binding on tetrahydroquinoline-CONHOMe Tier-2.
8. Computational vetting of design-around proposals (replaces v1 §E hand-waved suggestions)
DR4 v1 listed ZBG pivots as drop-in equivalents. Phase 7I tested 4 of them computationally; Part F now ranks pivots by evidence:
| Pivot (DR4 v1) | Charge state | Phase 7I status | Verdict |
|---|---|---|---|
| CONHOMe (hydroxamate prodrug) | Neutral | Boltz +0.066, K1141 NZ 3.89 Å (tighter than CONHOH), ADMET 0/10 flags, APBS reduces TRPM4 by 3.24 | Recommended v5.3 lead |
| Phosphonate | −2 | Boltz +0.050, K1141 NZ 2.83–4.41 Å, ADMET 0/10 flags, RWM permeability blocked at pH 7.4 (P ≈ 10⁻¹³ cm/s — di-anionic, f_neutral ≈ 0) | Requires bis-POM ester or cyclic-phosphonate prodrug (cf. tenofovir disoproxil); off-target APBS likely worse |
| Imidazole / triazole (Suggestion 1) | Neutral (pKa ~7) | Not yet tested | Queue Phase 7J: re-dock + APBS rescore on STRC + 5 off-targets |
| Carbamoyl phosphonate (Suggestion 2 alt) | −2 | Not yet tested | Lower priority — same charge-state issues as phosphonate |
| Tetrahydroquinoline core (Suggestion 3) | Neutral aromatic disruption | Not yet tested | Required if §7 melanin binding fails |
| 3-OH-adamantyl tail (Suggestion 4) | Polar tail | Not yet tested | Optional; tail is not the load-bearing axis |
Phase 7J plan (next computational sprint): generate v5.3 library focused on (a) imidazole / triazole ZBG variants with adamantyl tail + Cl/CN/F R-substituents + (b) tetrahydroquinoline core CONHOMe + adamantyl variants; Vina dock + Phase 5d ensemble + ADMET-AI + Boltz-2 + APBS on STRC + 5 off-targets. Computational envelope: ~6 hours wall-time on Mac arm64 + Boltz-2 v52_rest11 turnaround on M5 Max GPU.
9. Top-5 wet-lab assays (re-prioritised)
DR4 v1’s Top-5 list, reordered by load-bearing impact for H01:
- Cochlear melanin / stria vascularis (§7) — local-route P0. Melanin-Sepharose binding (15k via Charles River) + in vivo gerbil EP ($30k via Turner Scientific). Gate before any in vivo dosing.
- TRPM4 / TMEM16A / KCNQ4 patch-clamp panel (§6) — load-bearing §7 caveat closure. Axon Bioservices or Charles River; ~$25k for 3-channel × 3-conc × CONHOH/CONHOMe-Cl/imidazole-Tier-2. Validates APBS off-target ranking.
- ADAM17 / MMP-1 / -9 / -13 enzymatic panel (§4.1) — IT-confined MSS-local risk. BPS Bioscience or Reaction Biology; ~$3k for 4-enzyme × 8-conc × 2-compound. Pass: IC₅₀ > 10 µM on all four.
- Hydroxamate plasma + cochlear esterase stability (§4.1, prodrug pathway) — LC-MS over 90 min in human plasma + perilymph homogenate (gerbil or chinchilla). ~$8k via WuXi or Eurofins. Pass: prodrug CONHOMe-Cl half-life > 30 min in plasma, cleavage in cochlear esterase fraction within 4 hr.
- Ames (with/without S9) + micronucleus (§4.1, hydroxamate genotox) — genotoxicity panel for any CONHOH-bearing compound. BioReliance or Charles River; ~$15k for OECD 471 + 487. Pass: negative both.
(2-aminoquinoline retinopathy in adult rodents is dropped from the systemic-route Top-5 — moot at projected IT systemic margin. NMDA / DPP-4 panels deferred to confirmatory, not gating.)
10. Bibliography (expanded from v1’s 7 URLs)
Marked as v3 owed: each citation will be tied to a primary source via QMD search + Crossref / PubMed lookup. Required citations include but are not limited to: Eastman Kodak US3446809A; FDA labels for vorinostat, panobinostat, belinostat, givinostat (Duvyzat); Achaogen ACHN-975 Phase 1 cardiovascular halt FDA briefing; marimastat Phase III MSS publications; Verpy 2008 stereocilin PNAS; Larsson 1993 melanin binding; Halgren 2009 SiteMap (already in use Phase 8h-lite); Salt 2001 perilymph kinetics; Schacht 2008 Auditory Trauma; Vaira 2024 Givinostat pediatric DMD PK; tenofovir disoproxil bis-POM phosphonate prodrug primary lit; Frequency Therapeutics FX-322 patent estate.
11. v3 owed list
- Quantitative IT-to-systemic AUC calculation (§5)
- 2-aryl-hydroxamate Lossen stability lit search (§4.1)
- Imidazole / triazole ZBG library + Phase 7J computational sprint (§8)
- Bibliography expansion to ~25 primary sources (§10)
- DR3 CRO cross-references for §9 assay vendors and prices (§9 numbers are estimates; verify against DR3)
- Patent counts from USPTO + EPO + Lens.org for SNHL small-molecule competitive landscape (DR4 v1 §A.5 unquantified)
- Cleanup of v1 cosmetic issues (blob:capacitor image refs lines 109/158/170; IP table row 49–50; §B.1 missing adult-data subsection)
Connections
- DR4 — Hydroxamic Acid + 2-Amino-Quinoline-3 Chemotype IP Landscape and Hidden Toxicity Liabilities — v1 (superseded as load-bearing source; retained as systemic-route reference)
- DR4_review_and_enhancements — review note that prescribed v2’s structure
- DR5_intratympanic_delivery_state_of_art — IT delivery state-of-art and hydroxamate-otoprotective reconciliation
- DR3_cro_wet_lab_handoff — vendor menu for §9 wet-lab assays
- STRC h01 Phase 8h-lite Light Computational Evidence Package 2026-04-26 — Tanimoto, K1141 NZ stability, RWM permeability anchors (incl. #6 Tier-1 refresh)
- STRC h01 Phase 8g-v2 APBS Off-Target Rescore 2026-04-26 — load-bearing §6 source
- STRC Pharmacochaperone Competitive White Space 2024-2026 — DR2 white-space confirmation
- STRC Hypothesis Ranking — H01 hub